I am planning to use a fluorescent streptavidin labeled conjugate. What are the storage conditions and shelf life for the lyophilized powder and reconstituted solution?
In the lyophilized powder form, the fluorescent streptavidin labeled conjugate is stable for six months when stored at -20 degrees C, desiccated, and protected from light. The reconstituted solution is stable for approximately six months when stored at 4 degrees C, protected from light, with the addition of sodium azide to a final concentration of 5 mM or thimerosal to 0.2 mM. For longer storage, we recommend dividing the solution into aliquots and freezing at -20 degrees C, protected from light. Avoid repeated freezing and thawing of the solution.
I am planning to use a fluorescent streptavidin labeled conjugate. How should I prepare the working solution of the conjugate?
The fluorescent streptavidin labeled conjugate solution can be made by dissolving the powder in 0.5-1.0 mL of PBS or other suitable buffer. For details, please refer to page 4 of the "Streptavidin and Fluorescent Conjugates of Streptavidin" manual (https://assets.fishersci.com/TFS-Assets/LSG/manuals/mp00888.pdf).
引用および参考文献 (92)
引用および参考文献
Abstract
SHAP potentiates the CD44-mediated leukocyte adhesion to the hyaluronan substratum.
Authors:Zhuo L,Kanamori A,Kannagi R,Itano N,Wu J,Hamaguchi M,Ishiguro N,Kimata K
Journal:The Journal of biological chemistry
PubMed ID:16702221
A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes.
Authors:Beeton C, Wulff H, Singh S, Botsko S, Crossley G, Gutman GA, Cahalan MD, Pennington M, Chandy KG
Journal:J Biol Chem
PubMed ID:12511563
T lymphocytes with unusually high expression of the voltage-gated Kv1.3 channel (Kv1.3(high) cells) have been implicated in the pathogenesis of experimental autoimmune encephalomyelitis, an animal model for multiple sclerosis. We have developed a fluoresceinated analog of ShK (ShK-F6CA), the most potent known inhibitor of Kv1.3, for detection of Kv1.3(high) cells ... More
Inhibition of platelet-derived growth factor-BB-induced receptor activation and fibroblast migration by hyaluronan activation of CD44.
Authors:Li L, Heldin CH, Heldin P
Journal:J Biol Chem
PubMed ID:16809345
'The extracellular matrix molecule hyaluronan was found to suppress platelet-derived growth factor (PDGF) beta-receptor activation and PDGF-BB-induced migration of primary human dermal fibroblasts. The suppressive effect of hyaluronan was neutralized by a monoclonal antibody that specifically inhibits hyaluronan binding to its receptor CD44. Moreover, co-immunoprecipitation experiments showed that the PDGF ... More
PKC putative phosphorylation site Ser235 is required for MIP/AQP0 translocation to the plasma membrane.
Authors:Golestaneh N, Fan J, Zelenka P, Chepelinsky AB,
Journal:Mol Vis
PubMed ID:18523655
'PURPOSE: To investigate the functional significance of MIP/AQP0 phosphorylation at serine(235). METHODS: MIP/AQP0 expression and cellular localization was studied in rat lens epithelia explants induced to differentiate by FGF-2. MIP wild type (WT) and MIP (S235A) mutant expression plasmids were constructed and transiently expressed in RK13 cells. Subcellular localization of ... More
An impaired transendothelial migration potential of chronic lymphocytic leukemia (CLL) cells can be linked to ephrin-A4 expression.
Authors:Trinidad EM, Ballesteros M, Zuloaga J, Zapata A, Alonso-Colmenar LM,
Journal:Blood
PubMed ID:19828693
'Chronic lymphocytic leukemia (CLL) cell migration into lymphoid tissues is an important aspect of the pathobiology of this disease. Here, we investigated the role of ephrin-A4 (EFNA4) in the transendothelial migration (TEM) capacity of CLL and normal B cells through interacting with endothelial EphA2 (erythropoietin-producing hepatocellular carcinoma). CLL cells showed ... More